Analysis of benzodiazepine withdrawal program managed by primary care nurses in Spain

被引：21

作者：

Lopez-Peig C. ^{[1
,6
]}

Mundet X. ^{[2
,3
]}

Casabella B. ^{[1
]}

Del Val J.L. ^{[2
]}

Lacasta D. ^{[4
]}

Diogene E. ^{[3
,5
]}

机构：

[1] Primary Care Center Raval, Sud. Institut Català de la Salut, 08001, Barcelona

[2] Unitat de Suport de la Recerca Barcelona Ciutat - IDIAP Jordi Gol, RedIAPP Institut Català de la Salut, 08025, Barcelona

[3] Universitat Autònoma de Barcelona, 08193, Bellaterra

[4] Primary Care Center la Salut, Institut Català de la Salut, 08914, Badalona

[5] Institut Català de Farmacologia, Barcelona

[6] Woodberry Practice, Enfield. NHS Trust, London, Winchmore Hill

来源：

BMC Research Notes | / 5卷 / 1期

关键词：

Benzodiazepine; Habituation drug therapy; Primary care;

D O I：

10.1186/1756-0500-5-684

中图分类号：

学科分类号：

摘要：

Background: Benzodiazepine (BZD), the long-term treatment of which is harmful for cognitive function, is widely prescribed by General Practitioners in Spain. Based on studies performed in other countries we designed a nurse-led BZD withdrawal program adapted to Spanish Primary Care working conditions. Results: A pseudo-experimental (before-after) study took place in two Primary Care Centres in Barcelona. From a sample of 1150 patients, 79 were identified. They were over 44 years old and had been daily users of BZD for a period exceeding six months. Out of the target group 51 patients agreed to participate. BZD dosage was reduced every 2-4 weeks by 25% of the initial dose with the optional support of Hydroxyzine or Valerian. The rating measurements were: reduction of BZD prescription, demographic variables, the Short-Form Health Survey (SF-12) to measure quality of life, the Medical Outcomes Study (MOS) Sleep Scale, and the Goldberg Depression and Anxiety Scale. By the end of the six-month intervention, 80.4% of the patients had discontinued BZD and 64% maintained abstinence at one year. An improvement in all parameters of the Goldberg scale (p <0.05) and in the mental component of SF-12 at 3.3 points (p = 0.024), as well as in most components of the MOS scale, was observed in the group that had discontinued BZD. No significant differences in these scales before and after the intervention were observed in the group that had not discontinued. Conclusions: At one year approximately 2/3 of the patients had ceased taking BZD. They showed an overall improvement in depression and anxiety scales, and in the mental component of the quality of life scale. There was no apparent reduction in the sleep quality indicators in most of the analysed components. Nurses in a Primary Care setting can successfully implement a BZD withdrawal program. © 2012 Lopez-Peig et al; licensee BioMed Central Ltd.

引用

共 33 条

[11]

Monton C., Perez-Echeverria M., Campos R., Cols Y., Escalas de ansiedad y depresión de Goldberg: Una guía de entrevista eficaz para la detección del malestar psíquico, Aten Primaria, 12, 6, pp. 345-349, (1993)

[12]

Ashton H., The treatment of benzodiazepine dependence, Addiction, 89, 11, pp. 1535-1541, (1994)

[13]

Linden M., Bar T., Geiselmann B., Patient treatment insistence and medication craving in long-term low-dosage benzodiazepine prescriptions, Psychological Medicine, 28, 3, pp. 721-729, (1998)

[14]

Croissant B., Grosshans M., Klein O., Diehl A., Mann K., Scheme-based benzodiazepine detoxification with oxcarbazepine: A case report, Pharmacopsychiatry, 38, 5, pp. 222-223, (2005)

[15]

Finkel J.C., Johnson Y.J., Quezado Z.M.N., The use of dexmedetomidine to facilitate acute discontinuation of opioids after cardiac transplantation in children, Critical Care Medicine, 33, 9, pp. 2110-2112, (2005)

[16]

Lemoine P., Touchon J., Billardon M., Comparaison de 6 differentes modalites de sevrage du lorazepam une etude controlee, hydroxyzine versus placebo, Encephale, 23, 4, pp. 290-299, (1997)

[17]

Rosenbaum J.F., Attitudes toward benzodiazepines over the years, J Clin Psychiatry, 66, 2, (2005)

[18]

McGregor C., Machin A., White J.M., In-patient benzodiazepine withdrawal: Comparison of fixed and symptom-triggered taper methods, Drug and Alcohol Review, 22, 2, pp. 175-180, (2003)

[19]

Morin C.M., Bastien C., Guay B., Radouco-Thomas M., Leblanc J., Vallieres A., Randomized clinical trial of supervised tapering and cognitive behavior therapy to facilitate benzodiazepine discontinuation in older adults with chronic insomnia, American Journal of Psychiatry, 161, 2, pp. 332-342, (2004)

[20]

Baillargeon L., Landreville P., Verreault R., Beauchemin J.-P., Gregoire J.-P., Morin C.M., Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: A randomized trial, Canadian Medical Association Journal, 169, 10, pp. 1015-1020, (2003)

← 1 2 3 4 →